Thomas John Dietz, Director at Eiger BioPharmaceuticals, Inc. (EIGR), bought 5,000 shares at $11.26 ($56K) on 2018-12-06, disclosed to the SEC on 2018-12-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| EIGR | SELL | 2022-12-27 | $26K | — | Filing → |
| EIGR | BUY | 2021-04-12 | $21K | — | Filing → |
| EIGR | BUY | 2020-03-17 | $5K | — | Filing → |